Medicus Pharma Ltd.
MDCX.V
TSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 134.16% | 66.51% | 58.17% | 76.50% | 79.40% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 129.34% | 91.91% | 88.27% | 153.28% | 150.72% |
| Operating Income | -129.34% | -91.91% | -88.27% | -153.28% | -150.72% |
| Income Before Tax | -323.84% | -297.34% | -76.54% | -122.54% | -109.90% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -323.84% | -297.34% | -76.54% | -122.54% | -109.90% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -323.84% | -297.34% | -76.54% | -122.54% | -109.90% |
| EBIT | -129.34% | -91.91% | -88.27% | -153.28% | -150.72% |
| EBITDA | -- | 53.12% | -11.03% | -434.86% | -- |
| EPS Basic | -130.58% | -114.41% | 38.96% | 33.00% | 43.95% |
| Normalized Basic EPS | -87.60% | -71.69% | 38.68% | 31.92% | 43.07% |
| EPS Diluted | -198.04% | -114.41% | 38.96% | 33.00% | 43.95% |
| Normalized Diluted EPS | -87.60% | -71.69% | 38.68% | 31.92% | 43.07% |
| Average Basic Shares Outstanding | 71.74% | 66.80% | 79.62% | 105.33% | 166.77% |
| Average Diluted Shares Outstanding | 71.74% | 66.80% | 79.62% | 105.33% | 166.77% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |